A practical approach to allergic rhinitis and sleep disturbance management

Allergy and Asthma Proceedings

Volumn 27, Issue 3, 2006, Pages 224-230

  Davies, Michael J ^a   Fisher, Laura H ^a   Chegini, Soheil ^a   Craig, Timothy J ^a,b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CIRCADIAN RHYTHM; HAY FEVER; HUMAN; PATHOPHYSIOLOGY; PERENNIAL RHINITIS; PHYSIOLOGY; SLEEP DISORDER;

CIRCADIAN RHYTHM; HUMANS; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; SLEEP DISORDERS;

EID: 33746627715     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: 10.2500/aap.2006.27.2858     Document Type: Article

References (52)

1. Juniper EF, Rohrbaugh T, and Meltzer EO. A questionnaire to measure quality of life in adults with nocturnal allergic rhinoconjunctivitis. J Allergy Clin Immunol 111:484-490, 2003.
2. Juniper EF. Rhinitis management: The patient's perspective. Clin Exp Allergy 28(suppl 6):34-38, 1998.
3. Thompson AK, Juniper E, and Meltzer EO. Quality of life in patients with allergic rhinitis. Ann Allergy Asthma Immunol 85:338-348, 2000.
4. Flemons WW, and Tsai W. Quality of life consequences of sleep-disordered breathing. J Allergy Clin Immunol 99:S750-S756, 1997.
5. Lavie P, Gertner R, Zomer J, and Podoshin L. Breathing disorders in sleep associated with "microarousals" in patients with allergic rhinitis. Acta Otolaryngol 92:529-533, 1981.
6. Grosclaude M, Mees K, Pinelli ME, et al. Cetirizine and pseudoephedrine retard, given alone or in combination, in patients with seasonal allergic rhinitis. Rhinology 35:67-73, 1997.
7. Rundcrantz H. Postural variations of nasal patency. Acta Otolaryngol 68:435-443, 1969.
8. Young T, Finn L, and Kim H. Nasal obstruction as a risk factor for sleep-disordered breathing. The University of Wisconsin Sleep and Respiratory Research Group. J Allergy Clin Immunol 99:S757-S762, 1997.
9. McNicholas WT, Tarlo S, Cole P, et al. Obstructive apneas during sleep in patients with seasonal allergic rhinitis. Am Rev Respir Dis 126:625-628, 1982.
10. McColley SA, Carroll JL, Curtis S, et al. High prevalence of allergic sensitization in children with habitual snoring and obstructive sleep apnea. Chest 111:170-173, 1997.
11. Craig TJ, Teets S, Lehman EB, et al. Nasal congestion secondary to allergic rhinitis as a cause of sleep disturbance and daytime fatigue and the response to topical nasal corticosteroids. J Allergy Clin Immunol 101:633-637, 1998.
12. Vuurman EF, van Veggel LM, Uiterwijk MM, et al. Seasonal allergic rhinitis and antihistamine effects on children's learning. Ann Allergy 71:121-126, 1993.
13. Kessler RC, Almeida DM, Berglund P, and Stang P. Pollen and mold exposure impairs the work performance of employees with allergic rhinitis. Ann Allergy Asthma Immunol 87:289-295, 2001.
14. Tanner LA, Reilly M, Meltzer EO, et al. Effect of fexofenadine HCl on quality of life and work, classroom, and daily activity impairment in patients with seasonal allergic rhinitis. Am J Manag Care 5(suppl 4):S235-S247, 1999.
15. Hughes K, Glass C, Ripchinski M, et al. Efficacy of the topical nasal steroid budesonide on improving sleep and daytime somnolence in patients with perennial allergic rhinitis. Allergy 58:380-385, 2003.
16. Spaeth J, Klimek L, and Mosges R. Sedation in allergic rhinitis is caused by the condition and not by antihistamine treatment. Allergy 51:893-906, 1996.
17. Calhoun WJ. Nocturnal asthma. Chest 123(suppl 3):399S-405S, 2003.
18. Aoyagi M, Watanabe H, Sekine K, et al. Circadian variation in nasal reactivity in children with allergic rhinitis: Correlation with the activity of eosinophils and basophilic cells. Int Arch Allergy Immunol 120(suppl 1):95-99, 1999.
19. 4 and histamine excretion rates in normal subjects and patients with mild-to-moderate asthma. J Allergy Clin Immunol 96:643-651, 1995.
20. Kraft M, Vianna E, Martin RJ, and Leung DY. Nocturnal asthma is associated with reduced glucocorticoid receptor binding affinity and decreased steroid responsiveness at night. J Allergy Clin Immunol 103:66-71, 1999.
21. Nimmagadda SR, Szefler SJ, Spahn JD, et al. Allergen exposure decreases glucocorticoid receptor binding affinity and steroid responsiveness in atopic asthmatics. Am J Respir Crit Care Med 155:87-93, 1997.
22. White M. Mediators of inflammation and the inflammatory process. J Allergy Clin Immunol 103:S378-S381, 1999.
23. Naclerio R. Clinical manifestations of the release of histamine and other inflammatory mediators. J Allergy Clin Immunol 103:S382-S385, 1999.
24. 2 receptor-mediated airway goblet cell secretion and its modulation by histamine-degrading enzymes. J Allergy Clin Immunol 99:233-238, 1997.
25. Rajakulasingam K, Polosa R, Lau LC, et al. Comparative nasal effects of bradykinin and histamine: Influence on nasal airways resistance and plasma protein exudation. Thorax 48:324-329, 1993.
26. 1 receptors in human brain. Life Sci 72:409-414, 2002.
27. 4 on nasal mucosal blood flow, nasal airway resistance, and nasal secretion in humans. Clin Allergy 16:289-297, 1986.
28. 4 in allergic rhinitis. Ann Allergy 60:537-540, 1988.
29. Meltzer EO. Role for cysteinyl leukotriene receptor antagonist therapy in asthma and their potential role in allergic rhinitis based on the concept of "one linked airway disease." Ann Allergy Asthma Immunol 84:176-187, 2000.
30. Philip G, Malmstrom K, Hampel FC, et al. Montelukast for treating seasonal allergic rhinitis: A randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy 32:1020-1028, 2002.
31. Mullington JM, Hinze-Seich D, and Pollmacher T. Mediators of inflammation and their interaction with sleep: Relevance for chronic fatigue syndrome and related conditions. Ann N Y Acad Sci 933:201-210, 2001.
32. Krouse HJ, Davis JE, Krouse JH. Immune mediators in allergic rhinitis and sleep. Otolaryngol Head Neck Surg 126:607-13, 2002.
33. Arimura A, Yasui K, Kishino J, et al. Prevention of allergic inflammation by a novel prostaglandin receptor antagonist, s-5751. J Pharmacol Exp Ther 298:411-419, 2001.
34. Naclerio RM, Proud D, Togias AG, et al. Inflammatory mediators in late antigen-induced rhinitis. N Engl J Med 313:65-70, 1985.
35. Proud D, Reynolds CJ, Lacapra S, et al. Nasal provocation with bradykinin induces symptoms of rhinitis and a sore throat. Am Rev Respir Dis 137:613-616, 1988.
36. Rubinstein I. Nasal inflammation in patients with obstructive sleep apnea. Laryngoscope 105:175-177, 1995.
37. Devillier P, Dessanges JF, Rakotosihanaka F, et al. Nasal response to substance P and methacholine in subjects with and without allergic rhinitis. Eur Respir J 1:356-361, 1988.
38. Howarth PH. Mediators of nasal blockage in allergic rhinitis. Allergy 52:12-18, 1997.
39. Lieb K, Ahlvers K, Dancker K, et al. Effects of the neuropeptide substance P on sleep, mood, and neuroendocrine measures in healthy young men. Neuropsychopharmacology 27:1041-1049, 2002.
40. Wilson AM, Sims EJ, McFarlane LC, and Lipworth BJ. Effects of intranasal corticosteroids on adrenal, bone, and blood markers of systemic activity in allergic rhinitis. J Allergy Clin Immunol 102:598-604, 1998.
41. Nguyen KL, Lauver D, Kim I, and Aresery M. The effect of a steroid "burst" and long-term, inhaled fluticasone propionate on adrenal reserve. Ann Allergy Asthma Immunol 91:38-43, 2003.
42. Bousquet J, van Cauwenberge P, and Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 108:S147-S334, 2001.
43. Nayak AS, and Schenkel E. Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy 56:1077-1080, 2001.
44. Weiler JM, Bloomfield JR, Woodworth GG, et al. Effects of fexofenadine, diphenhydramine, and alcohol on driving performance. A randomized, placebo-controlled trial in the Iowa driving simulator. Ann Intern Med 132:354-363, 2000.
45. Saengpanich S, Assanasen P, de Tineo M, et al. Effects of intranasal azelastine on the response to nasal allergen challenge. Laryngoscope 112:47-52, 2002.
46. Golden S, Teets SJ, Lehman EB, et al. Effect of topical nasal azelastine on the symptoms of rhinitis, sleep, and daytime somnolence in perennial allergic rhinitis. Ann Allergy Asthma Immunol 85:53-57, 2000.
47. Meltzer EO, Orgel HA, Bronsky EA, et al. Ipratropium bromide aqueous nasal spray for patients with perennial allergic rhinitis: A study of its effect on their symptoms, quality of life, and nasal cytology. J Allergy Clin Immunol 90:242-249, 1992.
48. Milgrom H, Biondi R, Georgitis JW, et al. Comparison of ipratropium bromide 0.03% with beclomethasone dipropionate in the treatment of perennial rhinitis in children. Ann Allergy Asthma Immunol 83:105-111, 1999.
49. Numata T, Konno A, Yamakoshi T, et al. Comparative role of peptide leukotrienes and histamine in the development of nasal mucosal swelling in nasal allergy. Ann Otol Rhinol Laryngol 108:467-473, 1999.
50. 4-receptor antagonist, ICI 204,219, relieves symptoms of acute seasonal allergic rhinitis. Am J Respir Crit Care Med 151:1734-1739, 1995.
51. Van Adelsberg J, Philip G, LaForce CF, et al. Randomized controlled trial evaluating the clinical benefit of montelukast for treating spring seasonal allergic rhinitis. Ann Allergy Asthma Immunol 90:214-222, 2003.
52. Nayak AS, Philip G, Lu S, et al. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: A multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann Allergy Asthma Immunol 88:592-600, 2002.